Literature DB >> 14616695

Vancomycin-resistant Staphylococcus aureus: no apocalypse now.

F W Goldstein, M D Kitzis.   

Abstract

The number of reports concerning vancomycin-resistant Staphylococcus aureus is much higher than the number of true resistant strains or unexpected clinical failures. Many confounding factors, including inadequate serum levels, severely ill patients, foreign devices or undrained abscesses, are more likely to be responsible for the clinical failures than resistance to vancomycin.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14616695     DOI： 10.1046/j.1469-0691.2003.00734.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  10 in total

1.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

2.  Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.

Authors:  T R Anderegg; R N Jones; H S Sader
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

3.  Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Asllan Gjinovci; Manuela Bento; Dongmei Li; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate.

Authors:  T-D Huang; C Almpanis; O Denis; C Nonhoff; B Delaere; Y Glupczynski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-06       Impact factor: 3.267

5.  Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jeffrey Fernandez; Darren Abbanat; Wenchi Shang; Wenping He; Karen Amsler; James Hastings; Anne Marie Queenan; John L Melton; Alfred M Barron; Robert K Flamm; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

6.  Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors:  Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal:  Int J Antimicrob Agents       Date:  2009-02-23       Impact factor: 5.283

7.  Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.

Authors:  Adriana Renzoni; Patrice Francois; Dongmei Li; William L Kelley; Daniel P Lew; Pierre Vaudaux; Jacques Schrenzel
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus.

Authors:  Hideki Maki; Nadine McCallum; Markus Bischoff; Akihito Wada; Brigitte Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia.

Authors:  Li-Qing Bi; Jing Zhou; Ming Huang; Su-Ming Zhou
Journal:  Pak J Med Sci       Date:  2013-05       Impact factor: 1.088

10.  A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).

Authors:  Andreas Voss; Johan W Mouton; Erika P van Elzakker; Ron G Hendrix; Wil Goessens; Jan A Kluytmans; Paul F Krabbe; Han J de Neeling; Jacobus H Sloos; Nefise Oztoprak; Robin A Howe; Timothy R Walsh
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-09-24       Impact factor: 3.944
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.